Fresh from news of a “complete response” from other clinical trials last week, Imugene (ASX: IMU) has now dosed the first patient with a...

In an Australian first, clinical cancer researcher and developer Imugene (ASX: IMU) will launch its first “azer-cel” clinical trial...

Clinical-stage immuno-oncology company Imugene (ASX: IMU) is celebrating more than two years’ “complete response” for one of its bile...

Imugene (ASX: IMU) has landed a prized United States Food and Drug Administration (FDA) orphan drug approval for its bile tract cancer...

The first two blood cancer patients taking part in a United States-based trial, who had suffered relapses despite having treatment, have...

Imugene (ASX: IMU) has dosed its first of 10 Australian patients with its potent “VAXINIA” therapy as part of its phase-one bile tract...

Imugene (ASX: IMU) has confirmed the delivery of its first “onCARlytics” combination therapy dose to a bile duct cancer patient in the...

Australian anti-cancer company Imugene (ASX: IMU) has stamped a strategic manufacturing and processing agreement with Kincell Bio, with...

ASX-listed medical technology company Imugene (ASX: IMU) has launched a pivotal expansion study targeting patients with bile tract...

Australian anti-cancer company Imugene (ASX: IMU) has received a patent to protect its unique cancer treatment in China – the largest and...

Imugene (ASX: IMU) has cleared the first hurdle in its clinical trial to test the safety and efficacy of its “onCARlytics” treatment for...

An Australian-based medical mission to flesh out and kill cancerous cells in humans has received a boost after ASX-listed medtech Imugene...

Following recent successes, Imugene has advanced its Phase 1 clinical study with the first Cohort 5 patients now receiving doses of the...

Clinical stage immune-oncology company Imugene has reported some eye-catching results in an update of its Phase 1 trial to assess the...

Imugene has joined with United States-based NeoImmuneTech (NIT) for a two-year collaboration aimed at combining their respective...

Imugene expects to secure a crucial patent for its “PD1-Vaxx” lung cancer vaccine from the European Patent Office this month, with a...

The US Food and Drug Administration has stamped Imugene’s “Vaxinia” drug trials aimed at treating bile duct cancer with “fast-track”...

Cancer. In modern days of fast vehicles and seemingly even faster living, there are few people or families who have not been touched by some form of the insidious disease. From the breast to the brain, or the kidneys to the ovaries, the bastard thing seems to be almost everywhere. But there is hope – and thankfully, companies such as Imugene are trying desperately and cleverly to give us all more if it. And the company’s multi=pronged mission aimed at beating cancer is clearl

Imugene has continued to set the ASX boards alight after revealing it had delivered the first dose of its azer-cel therapy to a patient...

Australian immune-oncology company Imugene has recorded positive early signals from the first phase of its metastatic advanced solid...